Q32 Bio reports Q4 net income of $57.7M; Phase 2a SIGNAL-AA enrollment complete; cash runway into Q4 2027

Q32 Bio Inc.

Completed enrollment in Part B of SIGNAL-AA Phase 2a for alopecia areata; 36-week topline data expected mid-2026.
Completed $10.5M registered direct offering in Feb 2026; cash $48.3M at Dec 31, 2025, plus RDO and milestones fund ops into Q4 2027.
Sold ADX-097 to Akebia Therapeutics for $12M upfront/near-term milestone; up to $592M in milestones plus royalties.
Terminated all remaining obligations to Amgen via one-time equity grant; no future payments to Amgen.
Net income $57.7M in Q4 2025 and $29.8M for FY 2025 vs net loss prior year; EPS $4.58 diluted.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.